Role of predictive biomarkers and tumor mutational profile in selecting patients with platinum-refractory head-and-neck cancers for immune checkpoint inhibitor monotherapy: Where do we stand?
暂无分享，去创建一个
[1] Shikhar Kumar. A perfect biomarker for immune checkpoint inhibition - An elusive goal? , 2021, Cancer Research, Statistics, and Treatment.
[2] A. Klinakis,et al. TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection , 2020, EBioMedicine.
[3] Hung-Ming Wang,et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.
[4] K. Harrington,et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) , 2019, Journal of Immunotherapy for Cancer.
[5] B. Rangarajan,et al. Beyond the tumor and tumor milieu - Factors affecting responses to immunotherapy , 2019, Cancer Research, Statistics, and Treatment.
[6] J. Lunceford,et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.
[7] Chepsy C. Philip,et al. Cancer care: Challenges in the developing world , 2018, Cancer Research, Statistics, and Treatment.